Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

DSpace/Manakin Repository

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

Citable link to this page

 

 
Title: Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
Author: Dumurgier, Julien; Schraen, Susanna; Gabelle, Audrey; Vercruysse, Olivier; Bombois, Stéphanie; Laplanche, Jean-Louis; Peoc’h, Katell; Sablonnière, Bernard; Kastanenka, Ksenia V; Delaby, Constance; Pasquier, Florence; Touchon, Jacques; Hugon, Jacques; Paquet, Claire; Lehmann, Sylvain

Note: Order does not necessarily reflect citation order of authors.

Citation: Dumurgier, J., S. Schraen, A. Gabelle, O. Vercruysse, S. Bombois, J. Laplanche, K. Peoc’h, et al. 2015. “Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study.” Alzheimer's Research & Therapy 7 (1): 30. doi:10.1186/s13195-015-0114-5. http://dx.doi.org/10.1186/s13195-015-0114-5.
Full Text & Related Files:
Abstract: Introduction: The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ), tau and phosphorylated tau (p-tau181) are now used for the diagnosis of Alzheimer’s disease (AD). Aβ40 is the most abundant Aβ peptide isoform in the CSF, and the Aβ 42/40 ratio has been proposed to better reflect brain amyloid production. However, its additional value in the clinical setting remains uncertain. Methods: A total of 367 subjects with cognitive disorders who underwent a lumbar puncture were prospectively included at three French memory centers (Paris-North, Lille and Montpellier; the PLM Study). The frequency of positive, negative and indeterminate CSF profiles were assessed by various methods, and their adequacies with the diagnosis of clinicians were tested using net reclassification improvement (NRI) analyses. Results: On the basis of local optimum cutoffs for Aβ42 and p-tau181, 22% of the explored patients had indeterminate CSF profiles. The systematic use of Aβ 42/40 ratio instead of Aβ42 levels alone decreased the number of indeterminate profiles (17%; P = 0.03), but it failed to improve the classification of subjects (NRI = −2.1%; P = 0.64). In contrast, the use of Aβ 42/40 ratio instead of Aβ42 levels alone in patients with a discrepancy between p-tau181 and Aβ42 led to a reduction by half of the number of indeterminate profiles (10%; P < 0.001) and was further in agreement with clinician diagnosis (NRI = 10.5%; P = 0.003). Conclusions: In patients with a discrepancy between CSF p-tau181 and CSF Aβ42, the assessment of Aβ 42/40 ratio led to a reliable biological conclusion in over 50% of cases that agreed with a clinician’s diagnosis. Electronic supplementary material The online version of this article (doi:10.1186/s13195-015-0114-5) contains supplementary material, which is available to authorized users.
Published Version: doi:10.1186/s13195-015-0114-5
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450486/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:17295660
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters